表紙
市場調查報告書

注射劑和植入式醫療設備

Injectables and Implantables

出版商 FirstWord 商品編碼 940409
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
注射劑和植入式醫療設備 Injectables and Implantables
出版日期: 2020年03月18日內容資訊: 英文
簡介

近年來,用於控制釋放(CR)和長期釋放(PR)的注射劑和植入式醫療設備的發展取得了長足的進步。結果,增加了患者的自由度並且提高了依從性(患者依從性的依從性)。預計未來可注射和可植入醫療設備將為製藥和醫療設備行業提供主要的市場機會。另一方面,有許多問題需要克服,例如成本負擔,監管認證,足夠的證據積累以及在新興國家的滲透。

本報告分析了注射劑和植入式醫療器械的最新技術和市場趨勢,這是當今藥物輸送(藥物輸送)的重要組成部分,並基於與行業利益相關者的訪談,我們正在研究和考慮預期的效果,特別有效的治療領域,未來需要解決的問題以及未來市場機會的規模和方向。

分析大綱

分析方法和目的

主要注意事項:摘要

需要考慮的問題和內容

  • 注射和植入式醫療設備市場的重大機遇
    • 問題概述
    • 問題內容
    • 重要考慮
    • 引用根據
    • 來源
  • 依從性和患者預後的改善
  • 可注射和可植入醫療設備受益最大的治療領域
  • 醫療費用報銷問題
  • 監管審批問題
  • 臨床療效的實際證據
  • 限制新興國家對注射劑和植入式醫療設備的訪問
  • 注射劑和植入式醫療設備的未來潛力
目錄
Product Code: 596201653

Injectables and implantables are key to advancing patient centricity and adherence

The development of controlled and prolonged release injectable and implantable drugs has seen huge leaps forward in recent years. Increasing prevalence of chronic diseases; innovative technological advancements; growth in complex therapies such as biologics: together these factors create the potential for drug delivery solutions which offer greater patient freedom and improved adherence. Which disease areas offer the best opportunities for injectables and implantables? And what is the current position on core issues such as reimbursement, real world evidence and regulation? Now you can find out the answers to these crucial questions and more.

  • Who, what, why: Which pharma and medtech companies are making progress? What new implantable devices and novel injectable drugs have reached the market? Which therapy areas can benefit most and why?
  • The finance issues: Up-front cost is not the only consideration; long-term adherence can be significantly improved with injectables or implantables use. So, what are the factors causing payer reluctance? And how should real world evidence form part of the solution?
  • The regulatory issues: What is the current position regarding regulatory approval for injectables and implantables? And what local and global challenges must be overcome before proceeding?
  • The patient perspective: Understand how injectables and implantables make a significant difference to patient outcomes, improve adherence, and enhance quality of life.
  • The physician perspective: What more should pharma do to educate and encourage doctors to opt for injectables and implantables? Is enough being done to evidence efficacy and safety as well as patient advantages?

What to expect from this report

This report offers an up-to-date view of the fast-developing injectables and implantables market, identifying the key opportunities as well as recognising the challenges and barriers facing pharma companies looking to invest in this promising area. Delving into a wide range of issues from regulation to real world evidence to ethics and social constraints, The FutureViews Injectables and Implantables report provides the experts' view of the market to inform current and future investment strategy.

What did we do?

  • We identified 8 current issues regarding injectables and implantables
  • We explored these via secondary research to develop 15 targeted questions that we put to leading experts
  • We used all of this to identify 30 unique new insights
  • Insights are supported by 45 directly quoted comments and 60 additional source references

Example insight included in Injectables and Implantables

" If pharma is to provide access to injectables/implantables to emerging markets, it must address storage issues and social barriers. Many lower- and middle-income countries are also in regions of the world where elevated temperatures that would require cold storage for biologics. Injectables/implantables will also require aseptic facilities of manufacturing. Without adequate storage and aseptic facilities, medicines could be at risk for contamination. Additionally, manufacturers may encounter social and religious barriers to the use of some medicines such as contraceptives and vaccines: these must first be identified so that pharma can adopt storage-friendly formulations and devise culturally sensitive solutions to adoption barriers."

Example quote included in Injectables and Implantables

"Like all novel technologies entering the medical marketplace, clinician and patient adoption is indicative of a successful product. The pharma market can do a lot to help educate and provide useful information to the public regarding the benefits and patient outcomes from utilising new technologies that are entering the marketplace in the space of drug delivery. The key to knowledge is spreading awareness." Idicula Mathew , Co-Founder & CEO, Hera Health Solutions, US.

The expert panel for Injectables and Implantables

  • René Holm , Head and Scientific Director of Drug Product Development - Liquids & Parenterals at The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J).
  • Idicula Mathew , CEO and co-founder of Hera Health Solutions, a pharmaceutical device start-up that specialises in the development and commercialisation of long-acting treatments through proprietary biodegradable drug delivery implants.
  • Christopher Rhodes PhD , President, CEO and Founder of Drug Delivery Experts, a boutique drug product development firm that supports pharma and biotech companies on the research, development and translation of drug delivery systems from ideation to R&D, and on to commercialisation.

Why this report is important

Improving adherence is one of the biggest challenges facing pharma; it's also perhaps the most powerful benefit of injectables and implantables. Longer lasting medication means less frequent delivery, which in turn means fewer physician appointments and fewer lapses. More discrete administering of drugs is obviously preferable for patients. Injectables and implantables offer a way forward that is far easier and more convenient for all, and enables physicians to offer a holistic response as well as improved health outcomes.

Why FirstWord reports are different

  • 100% new content: You won't find old research presented as new. Guaranteed.
  • Opinions you need to hear: We only interview experts with current, relevant experience.
  • Professional researchers: The knowledge, experience and contacts to get the answers you need.

Table of Contents

Subject synopsis

Research methodology and objectives

  • Which experts were interviewed and why?

Key insights summary

Issues and insights

  • Key opportunities within the injectables and implantables market
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Improvement in adherence and patient outcomes
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Therapy areas to benefit the most from injectables and implantables
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Reimbursement issues
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
  • Challenges to regulatory approval
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Real-world evidence of clinical efficacy
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • Limited access to injectables and implantables in emerging countries
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits
  • The future of injectables and implantables
    • Issue summary
    • Questions
    • Key insights
    • Supporting quotes
    • Intelligence exhibits